13 June 2025

---

Sonendo Reports Growth, Tightens Cash Flow

---

Sonendo, Inc. (“Sonendo” or the “Company”) (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the first quarter ended March 31, 2025, and issued short- and long-term financial guidance.

Recent Highlights

• Generated $7.4 million of total revenue for the first quarter of 2025, representing 5% growth compared to the prior-year period;
• Drove a substantial increase in gross margin to 44% for the first quarter of 2025, up 1,600 basis points compared to the 28% gross margin for the prior-year period;
• Reported a 48% year-over-year improvement in adjusted EBITDA loss to $3.9 million for the first quarter of 2025;
• Significantly reduced free cash flow burn to $4.5 million, a 58% reduction compared to the prior-year period;
• Recently completed a $5.0 million private placement of its common stock, which included new and existing investors;
• Amended its credit facility to defer principal amortization payments until at least September 2025, and potentially until March 31, 2026.

“We are pleased that our lender and the new and existing investors who participated in the private placement have recognized the meaningful success we have achieved in restructuring the business and increasing revenue while significantly reducing operating expenses and free cash flow burn, as demonstrated in our first quarter 2025 financial and operational results,” said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. “We have significantly improved the liquidity profile of the Company, and we expect to deliver additional gross margin expansion and further reductions in operating losses and free cash flow burn in 2025. We remain steadfastly committed to operational excellence and to position Sonendo for robust, long-term, and profitable growth.”

As of March 31, 2025, the Company’s cash, cash equivalents, and short-term investments totaled $7.2 million, which does not include the $4.7 million in estimated net proceeds the Company received in the private placement. There was $14.2 million of principal outstanding under its credit facility.

Financial Guidance

The Company is providing the following short- and long-term financial guidance, which reflects management’s latest expectations.

About Sonendo

Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy, and advanced fluid dynamics to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure.

The clinical benefits of the GentleWave System, when compared to conventional methods of root canal therapy, include improved clinical outcomes such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing, and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices.

Source: www.sonendo.com